Policy Watch: 20 Regulatory Updates — June 22, 2026
This update covers DEA synthetic opioids schedule I placement actions affecting clinical and regulatory landscapes in 2026. These changes influence substance classification and patient care considerations. Stay informed on the latest controlled…
Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I
The DEA has issued the cumyl-pegaclone schedule i designation, reflecting its high abuse potential and lack of accepted medical use. This designation highlights regulatory efforts to control synthetic cannabinoids. Clinicians should be aware of the risks…
DEA Places Synthetic Cannabinoid CUMYL-PEGACLONE in Schedule I
The U.S. Drug Enforcement Administration has placed CUMYL-PEGACLONE, a synthetic cannabinoid analog, into Schedule I of the Controlled Substances Act due to its high abuse potential and lack of accepted medical use. This CUMYL-PEGACLONE Schedule I…
Policy Watch: DEA Schedule I Placement of Synthetic Cannabinoids — June 08, 2026
This Policy Watch covers DEA synthetic cannabinoids schedule I placement updates for June 08, 2026. These regulatory actions affect clinical and research practices involving controlled substances. Clinicians should stay informed about these changes to…
Policy Watch: Key Synthetic Cannabinoids Schedule I Updates — June 02, 2026
This policy watch highlights synthetic cannabinoids Schedule I updates 2026 with significant clinical and regulatory implications. The DEA's recent actions classify several synthetic cannabinoids as Schedule I substances, affecting clinicians and…